0 170

Cited 1 times in

Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer

 Byoung Soo Kwon  ;  Ji Hyun Park  ;  Seulgi Kim  ;  Sojung Park  ;  Wonjun Ji  ;  Woo Sung Kim  ;  Jae Cheol Lee  ;  Yu Rang Park  ;  Chang-Min Choi 
 Tumori, Vol.105(3) : 216-224, 2019 
Journal Title
Issue Date
Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage* ; Carcinoma, Non-Small-Cell Lung ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/epidemiology ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Middle Aged ; Mutation ; Neoplasm Staging ; Pemetrexed/administration & dosage ; Progression-Free Survival ; Protein Kinase Inhibitors/administration & dosage*
Advanced lung cancer ; EGFR-TKI ; Korea ; big data ; female
BACKGROUND: This study aimed to estimate therapeutic effects of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in real-world practice, by analyzing survival outcomes in an unselected, Korean female population with advanced lung cancer based on the National Health Insurance Service database. METHODS: We identified women with newly diagnosed advanced lung cancer from January 2004 to December 2013. For progression-free survival (PFS) and overall survival (OS) analyses, patients were defined into the following subgroups: group A, treated with first-generation EGFR-TKI ⩾6 months; group B, treated with EGFR-TKIs <6 months but at least >1 month; and group C, treated with cytotoxic chemotherapy as follows: monotherapy or combination therapy with gemcitabine or pemetrexed; or monotherapy with docetaxel, paclitaxel, or vinorelbine. RESULTS: Among 11,045 enrolled patients, 6170 (55.8%) were treated with first-generation EGFR-TKIs for at least 1 month. The median OS for patients treated with EGFR-TKIs was significantly longer than that of EGFR-TKI-naive patients (19.1 months [95% confidence interval (CI) 18.5-19.7] vs 9.5 months [95% CI 9.1-9.8], P<0.001). In subgroup analysis, group A had a significantly longer median OS compared with group B (30.3 months [95% CI 29.5-31.2] vs 12.3 months [95% CI 11.9-12.7], P<0.001). The median PFS of group A was significantly longer than that of group B (15.8 vs 3.7 months, P<0.001). CONCLUSIONS: Our analysis demonstrates that EGFR-TKIs confer significant PFS and OS benefits in the real-world practice for Korean female with advanced lung cancer.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
Yonsei Authors
Park, Yu Rang(박유랑) ORCID logo https://orcid.org/0000-0002-4210-2094
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.